TLS Prevention — RACP Paediatrics MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: D — IV hyperhydration (3 L/m2/day) and rasburicase (for high-risk patients)
TLS prevention: aggressive IV hyperhydration (2-3 L/m2/day) is the cornerstone. Rasburicase (recombinant urate oxidase) rapidly reduces uric acid and is preferred over allopurinol for high-risk patients (high tumour burden, high WCC, bulky disease). Monitoring of K+, PO4, Ca2+, urate, creatinine, and urine output is essential.
Reference: ANZCHOG – 2024 – Treatment Guidelines: Tumour Lysis Syndrome